The findings of a new neuroimmunology study could reframe scientists’ understanding of this complex biological system and aid the development of treatments for immune disorders https://t.co/Ypw6j0xtQq ...

Ampligen Program & Pipeline - Ampligen, an immuno-modulator, is the lead program with broad-spectrum activity demonstrated in human clinical studies[7] - The company is advancing a broad pipeline across multiple indications including Immuno-Oncology, Immune Disorders, and Viral Diseases[9] - The company plans to conduct a Phase 1/2 or Phase 2 study in collaboration with the University of Alabama-Birmingham, focusing on influenza, including avian influenza (Bird Flu)[10] Oncology Programs - The company is targeting multiple cancers with high unmet needs through immuno-therapy oncology programs[18] - In an Early Access Program for late-stage pancreatic cancer, the median overall survival (OS) was 19 months in the Ampligen cohort compared to 12 months for a well-matched historical control group[29] - The 19 months OS in Ampligen cohort represents 79 month increase survival benefit compared to current standard of care[29] - The company is enrolling and dosing patients in a Phase 2 study (DURIPANC) for Metastatic Pancreatic Ductal Adenocarcinoma, using Ampligen in combination with durvalumab[27] - Additional target oncology indications include Ovarian Cancer (19880 new cases annually), Breast Cancer (287850 new cases annually), Colorectal Cancer (151030 new cases annually), and Melanoma (99780 new cases annually)[26] Post-COVID Conditions - The company is exploring Ampligen as a potential treatment for Post-COVID Conditions, particularly fatigue, with a follow-up clinical trial planned[37] - Preliminary data from a study at the Hunter-Hopkins center showed improvements in exercise ability, overall fatigue levels, and post-exertional malaise in 4 patients treated for Long-COVID[38] - Final clinical study results on AMP-518 indicate that Ampligen improves measures of fatigue over placebo[42] Intellectual Property & Exclusivity - Ampligen has Orphan Drug Designation from the FDA and EMA, providing 7 years and 10 years of market exclusivity following approval, respectively[54] - The company has 46 patents worldwide and 72 pending applications[54]